Starpharma Holdings Ltd has released a press release.
VIRALEZE distribution agreement for Hong Kong and Macau
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- New clinical data for DEP cabazitaxel in prostate cancer
- S&P DJI Announces September 2022 Quarterly Rebalance
- Starpharma annual report and full year financial results
- Starpharma signs new DEP agreement with MSD
- Quarterly Activities Report & Appendix 4C
Later from Starpharma
- AGM Chairman address and CEO presentation
- Positive AZD0466 clinical data presented by AstraZeneca
- VIRALEZE Nasal Spray Registered in Indonesia
- Starpharma receives $7.1M R&D tax incentive refund
- Response to ASX Query Letters
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma